Randomized study comparing the efficacy of aprepitant with palonosetron as antiemetic drug during chemotherapy including cisplati
Not Applicable
- Conditions
- advanced or recurrent esophageal or gastric carcinoma
- Registration Number
- JPRN-UMIN000005623
- Lead Sponsor
- Kitasato University School of Medicine
- Brief Summary
The primary endpoint of complete response was not achieved, but AGD seems to be more effective than PD for the prevention of HEC-induced vomiting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Not provided
Exclusion Criteria
1. Serious heart disease, serious renal disease, serious liver disease, and poor controlled Diabetes 2. Woman during the pregnancy or with the possibility of the pregnancy 3. Patient with severe mental disorder 4. The allergic past history for the serotonin receptor antagonist 5. Patient with nausea, vomiting due to brain tumor or ileus 6. Patient who plans to receive radiotherapy for the chest, abdomen, or pelvis 7. Patient using antiemetic drug within 48 hours before chemotherapy 8.Patients who are judged inappropriate for the entry into this study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method complete response (no emesis and no rescue therapy) within 120 hours after the start of the first course of chemotherapy
- Secondary Outcome Measures
Name Time Method